Solve™ Platform
Jennerex's products are designed using the proprietary SOLVE™ (Selective Oncolytic Vaccinia Engineering) platform. SOLVE takes advantage of the natural attributes of poxviruses as well as their ability to be genetically engineered to produce safe, therapeutic viruses that can infect solid tumors both systemically and locally. SOLVE platform has the ability to produce novel, multi-functional products, such as JX-594, that can selectively express high concentrations of complementary therapeutics. We plan to continue employing SOLVE to create new therapeutics that broadly target different types of cancers in our early-stage pipeline.
